文献速递浆细胞疾病造血干细胞移植与细胞治疗

接受艾基奥仑赛治疗的多发性骨髓瘤患者肠道微生物组与代谢组和疗效及毒性相关性的纵向分析

Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel.
PubMed 文献 · Blood Adv · 2025-01-01

研究对33例接受艾基奥仑赛(ide-cel)抗B细胞成熟抗原CAR-T治疗的多发性骨髓瘤患者纵向采集117份粪便样本行全基因组鸟枪法测序。ide-cel输注后细菌多样性显著下降,细菌组成与疗效及毒性相关;基线存在菌属优势者≥2级细胞因子释放综合征(CRS)发生率为46.2%,高于无菌属优势者的11.1%(P = .043)。

要点

  • ide-cel输注后患者肠道细菌多样性显著下降。
  • 应答者中Flavonifractor plautii、Bacteroides thetaiotaomicron、Blautia fecis和Dysosmobacter菌种显著富集。
  • 基线菌属优势者≥2级CRS发生率为46.2%,无菌属优势者为11.1%(P = .043)。

核心结论

  • 研究揭示了ide-cel疗效与毒性相关的新微生物组关联,可能有助于开发改善CAR-T结局的方法。

研究设计与样本

  • 对33例接受ide-cel抗B细胞成熟抗原CAR-T治疗的多发性骨髓瘤患者,在不同时间点采集117份粪便样本行全基因组鸟枪法测序。

主要发现

  • ide-cel输注后细菌多样性显著下降,细菌组成与治疗应答和毒性存在显著差异。
  • ide-cel应答者中Flavonifractor plautii、Bacteroides thetaiotaomicron、Blautia fecis和Dysosmobacter菌种显著富集。
  • 以优势特定分类群(>35% prevalence)定义的微生物组重大破坏及兼性致病菌(如肠球菌属)增加与ide-cel毒性尤其细胞因子释放综合征(CRS)相关。
  • 基线样本存在菌属优势者≥2级CRS发生率为46.2%,无菌属优势者为11.1%(P = .043)。
  • 网络分析和粪便代谢物质谱评估显示,F plautii与应答者中吲哚代谢物及通路增加相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Increasing evidence suggests that the gut microbiome may influence the responses and toxicities associated with chimeric antigen receptor T-cell (CAR-T) therapy. We conducted whole-genome shotgun sequencing on stool samples (N = 117) collected at various times from patients with multiple myeloma (n = 33) who underwent idecabtagene vicleucel (ide-cel) anti-B-cell maturation antigen CAR-T therapy. We observed a significant decrease in bacterial diversity after ide-cel infusion, along with significant differences in the bacterial composition linked to therapy response and toxicities. Specifically, we found significant enrichment of Flavonifractor plautii, Bacteroides thetaiotaomicron, Blautia fecis, and Dysosmobacter species in ide-cel responders. A notable finding was the link of major microbiome disruption, defined as the presence of dominant specific taxa (>35% prevalence), and increased facultative pathobionts, like Enterococcus, with ide-cel toxicities, especially cytokine release syndrome (CRS). Patients with genus dominance in baseline samples had a higher incidence of grade 2 or higher CRS at 46.2% than those without genus dominance (11.1%; P = .043). In addition, network analysis and mass spectrometric assessment of stool metabolites revealed important associations and pathways, such as F plautii being linked to increased indole metabolites and pathways in responders. Our findings uncovered novel microbiome associations between ide-cel responses and toxicities that may be useful for developing modalities to improve CAR-T outcomes.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Saha S, Rehman L, Rehman A, et al. Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel. Blood Adv. 2025. PMID: 40198765. doi:10.1182/bloodadvances.2024014476

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。